Novo Nordisk (NVO) Stock Analysis

Company Profile

Novo Nordisk (NVO) trades as an ADR rather than ordinary local shares — read it with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Novo Nordisk (NVO) posts ROE of 58.38%, in the upper peer quartile. That suggests the company earns more from each dollar of shareholders’ equity than most industry peers, a useful capital-efficiency signal.

Novo Nordisk (NVO) keeps 33.92% of revenue as net profit on net margin, above the industry benchmark range. That is unusually strong bottom-line conversion, though tax effects, asset sales, or other one-off gains should be checked before treating it as durable.

Novo Nordisk (NVO) turns 40.05% of revenue into operating profit, putting operating margin in the upper peer quartile. Before financing and taxes enter the picture, the day-to-day business keeps more of each sales dollar than most industry peers.

Profitability Metrics

Growth

Novo Nordisk (NVO) grew revenue 6.43%, roughly around the peer group's normal range. Top-line momentum looks broadly typical for the industry.

Novo Nordisk (NVO) grew earnings per share 1.77%, roughly around the peer group's normal range. Bottom-line momentum looks broadly typical for the industry.

Growth Metrics

Financial Strength

Novo Nordisk (NVO) has current ratio of 0.85, in the tighter-liquidity quartile for its industry. The short-term cushion is thinner than most peers carry, even if the absolute comfort level still depends on the business model.

Novo Nordisk (NVO) has debt-to-equity ratio of 0.62, roughly in line with the peer group’s normal leverage range. Its mix of debt and equity looks typical for the industry.

Financial Strength Metrics

Dividends

Novo Nordisk (NVO) has dividend yield of 29.03%, above the entire industry range. That headline income is large, but yields this far above peers often come from a falling share price or an at-risk payout, so dividend safety matters more than the percentage itself.

Novo Nordisk (NVO) has payout ratio of 45.36%, above the peer distribution for its industry. The dividend consumes more reported earnings than peers normally do, leaving unusually thin earnings cover.

Dividend Metrics

Valuation

Novo Nordisk (NVO) trades at P/E ratio of 10.18, in the cheaper earnings-multiple quartile for its industry. Investors are paying less for each dollar of TTM earnings than they usually pay for comparable businesses.

Novo Nordisk (NVO) trades at 0.53 on P/S ratio, in the lower sales-valuation quartile for its industry. That points to a cheaper revenue stream than most peers, with margin quality still doing the heavy lifting.

Novo Nordisk (NVO) trades at 5.43 on P/B ratio, roughly in line with the industry’s normal price-to-book range. Its balance sheet is not being priced at a clear discount or premium versus peers.

Valuation Metrics